Barron's features IPOX® CEO Josef Schuster in an analysis of BitGo's upcoming $2 billion NYSE debut. Highlighting the crypto custodian's profitability as a key strength, Schuster notes that while financials are solid, recent market volatility suggests investors remain disciplined. He cautions that despite the hype, there won't be "indiscriminate demand" for the stock. The piece also examines the broader 2026 IPO landscape, including upcoming listings like EquipmentShare.

Reuters reports that construction tech firm EquipmentShare.com is targeting a $6.41 billion valuation in its upcoming U.S. IPO. IPOX® VP Kat Liu provided expert commentary in the article, noting that the firm’s T3 technology layer adds a "narrative premium" compared to traditional rental competitors. Liu also highlighted the company’s impressive growth trajectory, predicting "healthy demand" driven by the credibility of its narrative as it prepares to list on Nasdaq.

A recent Reuters article discusses BitGo's target of a $1.96 billion valuation in its upcoming IPO. IPOX® Associate Lukas Muehlbauer provides expert commentary, noting that recent market scrutiny has driven a "flight to quality," positioning BitGo as a defensive play due to its regulatory status. The piece also highlights BitGo’s strategic timing amid small-cap momentum, supported by its recent pivot to profitability and OCC approval as a national trust bank.

A recent Seeking Alpha analysis by Fred Piard identifies the First Trust US Equity Opportunities ETF (FPX), which tracks the IPOX® 100 U.S. Index, as the market's "most compelling" IPO fund. Piard notes that the ETF has significantly outperformed competitors and benchmarks since 2006, driven by the index’s unique methodology that captures value from both new listings and corporate spin-offs. He concludes that the fund's rules-based approach offers investors superior long-term returns compared to other strategies in the space.

Reuters features IPOX® VP Kat Liu’s analysis of Forgent Power Solutions’ robust IPO filing. Amid an 84% revenue surge, Liu discusses the strategic advantage of early 2026 timing and the constructive influence of strong peer performance. She provides critical insight into potential risks, including raw material costs and supply chain sensitivities, as the electrical equipment maker prepares for its NYSE debut.

Aktis Oncology surges 24% in the first major biotech IPO of 2026, with IPOX® Associate Lukas Muehlbauer highlighting its strategic backing. The U.S. pipeline accelerates as chat platform Discord and fitness app Strava confidentially file for listings, while President Trump weighs a massive Fannie Mae and Freddie Mac public offering. Additionally, Brazilian fintech PicPay files for a $500 million Nasdaq debut, signaling a robust return of large-cap issuers to the market.

In a recent Reuters article, IPOX® Associate Lukas Muehlbauer commented on Aktis Oncology’s upsized IPO, targeting a $945 million valuation with Eli Lilly as an anchor investor. Muehlbauer highlights that this backing validates Aktis’ technology and positions the firm as a strategic target in an M&A-driven sector. He views this as a positive signal for a selective biotech rebound in 2026, where investors increasingly favor proven, late-stage pipelines.

Bloomberg features IPOX® Analyst Lukas Muehlbauer on the trajectory of European listings since the 2021 IPO boom. Discussing InPost SA’s takeover offer, the article highlights the shift from a hype-driven seller’s market to a scrutiny-heavy buyer’s environment. Muehlbauer emphasizes that investors now prioritize credibility over "growth at all costs," fundamentally changing how new offerings are valued in the current market landscape.

In Europe, Octopus Energy spins off its tech arm Kraken at an $8.7 billion valuation to prepare for a future listing. Asia sees a surge in activity as VinFast affiliate GSM targets a massive $20 billion international IPO. Meanwhile, Chinese tech listings accelerate with Alibaba-backed AI unicorn MiniMax launching its $600 million Hong Kong debut and Baidu’s chip unit Kunlunxin filing for a spin-off, while regulators ease rules for rocket firms like LandSpace.

In a recent article, Benzinga featured the First Trust U.S. Equity Opportunities ETF (FPX), which tracks the IPOX® 100 U.S. Index, for being the first to add Medline Industries after its massive IPO. The piece highlights the fund's systematic, rules-based methodology, noting a 40% gain this year and a five-star Morningstar rating. This underscores how IPOX® indices provide investors with diversified, liquid access to top-performing new public companies like Medline.

Bill Ackman proposes a unique SpaceX merger, while Medtronic’s MiniMed and fleet AI firm Motive Technologies file for U.S. debuts. SoftBank delays its PayPay IPO to prioritize OpenAI funding, while China’s LandSpace and pet care group Ringpai advance listing plans. In Europe, Visma expands its syndicate for a blockbuster London deal, and Aegea files to break Brazil’s four-year IPO drought, as Seven & i accelerates its U.S. turnaround.

OpenAI and SpaceX headline the 2026 pipeline with potential $1 trillion+ valuations, fueling Nasdaq’s optimistic outlook. Andersen Group surged 31% in its debut, with IPOX® VP Kat Liu crediting strong brand recognition. In Europe, Elliott preps a London listing for Waterstones and Barnes & Noble. Meanwhile, a wave of Chinese AI and chip firms targets Hong Kong, while Saudi markets cool following EFSIM’s cancellation and CloudKitchens’ delay.

In a recent article by Reuters, tax advisory firm Andersen Group saw its shares surge 31% during its NYSE debut. Kat Liu, Vice President at IPOX, noted that investors are responding to the firm's unique brand legacy and earnings stability. With a $2.3 billion valuation, Andersen plans to use its new public currency for aggressive global acquisitions, signaling a revitalized momentum in the U.S. IPO market following recent interest rate cuts.

SpaceX dominates headlines with plans for a record-breaking IPO targeting a $1.5 trillion valuation. IPOX® CEO Josef Schuster weighs in on the blockbuster pipeline, while IPOX® Associate Lukas Muehlbauer analyzes Wealthfront’s debut and EquipmentShare’s filing. Tax firm Andersen targets a $1.75 billion deal, Michael Burry eyes a Fannie Mae re-listing, and Magnum completes its spin-off, while Hong Kong sees crypto and robotics activity.